<DOC>
	<DOC>NCT01938378</DOC>
	<brief_summary>To assess the safety and tolerability of octaplas™ in the pediatric population by monitoring serious adverse drug reactions, adverse drug reactions (ADRs), thrombotic events (TEs), thromboembolic events (TEEs) and by measuring safety laboratory parameters.</brief_summary>
	<brief_title>Octaplas Pediatric Plasma Exchange Trial</brief_title>
	<detailed_description />
	<criteria>1. Patients in whom therapeutic plasma exchange is required. 2. Patient is male or female ≥ 4 years to ≤ 20 years of age. 3. Patient must be a minimum of 15 kg and not require RBC priming for his/her plasma exchange machine. 4. Patient or patient's legal representative(s)/guardian(s) has /have given voluntarily written and signed informed consent before any studyrelated procedure is to be performed. If children are old enough (age usually deemed by each institution) to understand the risks and benefits of the study, they should also be informed and provide their written assent. 1. Patient with known homozygous congenital deficiency of Protein S. 2. Patient has a history of severe hypersensitivity reaction to plasmaderived products or to any excipient of the investigational product. 3. Patient has an already known IgA deficiency with documented antibodies against IgA. 4. Patient is currently participating in another interventional clinical study or has participated during the past 1 month prior to study inclusion. 5. Patient is pregnant. 6. Use of AngiotensinConvertingEnzymeinhibitors within 72 hours of the start of the first infusion episode or planned used of these medications while on study.</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Octaplas</keyword>
</DOC>